Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hugo Bakis1, Pierre Pfirmann1, Christian Combe2

  • 1Service de néphrologie, transplantation, dialyse et aphérèses, CHU de Bordeaux, F-33000 Bordeaux, France.

Nephrologie & Therapeutique
|December 30, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and factors associated with Herpes Zoster infection in kidney transplant recipients, a recent epidemiological study.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Depressive symptoms in chronic kidney disease: the hidden role of uremic toxins.

BMJ mental health·2026
Same author

Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis.

Nature communications·2026
Same author

Drug prescription for patients treated by dialysis: navigation in the fog.

Clinical kidney journal·2026
Same author

Kidney biopsy during pregnancy: indications, complications, results and therapeutic impact.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

French nephrologists’ practices in the management of anemia and iron deficiency in chronic kidney disease

Nephrologie & therapeutique·2026

Sodium glucose co-transporter type 2 inhibitors (iSGLT2) offer significant cardiovascular and kidney protection for patients with diabetes, heart failure, and chronic kidney disease (CKD). These iSGLT2 medications slow CKD progression and reduce albuminuria, particularly in patients with proteinuria.

Area of Science:

  • Nephrology and Endocrinology
  • Pharmacology of glucose metabolism and cardiovascular/renal protection

Context:

  • Sodium glucose co-transporter type 2 inhibitors (iSGLT2) represent a therapeutic breakthrough for managing complex conditions.
  • Evidence from randomized controlled trials demonstrates iSGLT2 efficacy in reducing cardiovascular risk in type 2 diabetes and heart failure.
  • Clinical studies like CREDENCE, DAPA-CKD, and EMPA-KIDNEY specifically investigated iSGLT2 benefits in chronic kidney disease (CKD).

Purpose:

  • To evaluate the nephroprotective effects of iSGLT2 in patients with chronic kidney disease (CKD).
  • To assess the impact of iSGLT2 on the progression of kidney disease, glomerular filtration rate (GFR), and albuminuria.
  • To review the benefits and risks of iSGLT2 in diverse CKD populations, including those with and without proteinuria.

Summary:

Keywords:
Chronic kidney diseaseDébit de filtration glomérulaireGliflozinGliflozineGlomerular filtration rateMaladie rénale chroniqueMortalityMortalitéProteinuriaProtéinurie

Related Experiment Videos

  • iSGLT2 significantly slow the progression of CKD, reduce the decline in GFR, and decrease albuminuria.
  • Nephroprotective effects are evident in CKD patients with proteinuria, regardless of diabetes status, as shown in DAPA-CKD and EMPA-KIDNEY.
  • iSGLT2 are recommended for optimal nephroprotection in CKD patients with type 2 diabetes, albuminuria, or heart failure, alongside RAS inhibitors and standard care.

Impact:

  • iSGLT2 expand the therapeutic options for CKD management, offering significant renal and cardiovascular benefits.
  • Personalized patient care considering underlying nephropathy is crucial for optimizing iSGLT2 therapy.
  • Monitoring for potential side effects like genital infections and euglycemic ketoacidosis is essential, particularly in diabetic patients.